Illustrative estimate only - not verified by this sponsor. Contact the study team for actual compensation.
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
What happens when you apply
Reach out via phone or email to express interest
Brief call to discuss your health history
Medical screening at the research site
Begin your journey in the study
Inclusion Criteria: * Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months. * Age ≥ 18 and able to read, understand and sign informed consent. * Must be willing to adhere to the treatment algorithm and time constraints therein. Exclusion Criteria: * Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.
imaguineapig pulls live data from ClinicalTrials.gov (NIH/NLM).Illustrative estimate only - not verifiedPay estimates are approximate ranges based on study type and are not confirmed by sponsors — actual compensation may differ. Eligibility indicators use limited criteria (age, sex) only. We do not provide medical advice. Always contact the study team directly to confirm compensation, full eligibility, and risks before enrolling.